FMP
Mirum Pharmaceuticals, Inc.
MIRM
NASDAQ
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
41.51 USD
0.38 (0.915%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Christopher Peetz
sector
Healthcare
industry
Biotechnology
website
https://www.mirumpharma.comexchange
NASDAQ
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
CIK
0001759425
ISIN
US6047491013
CUSIP
604749101
Address
950 Tower Lane
Phone
650 667 4085
Country
US
Employee
311
IPO Date
Jul 18, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MIRM Financial Summary
CIK
0001759425
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
604749101
ISIN
US6047491013
Country
US
Price
41.51
Beta
1.16
Volume Avg.
366.23k
Market Cap
1.99B
Shares
-
52-Week
23.14-48.89
DCF
0.79
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-19.96
P/B
-
Website
https://www.mirumpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MIRM News
It looks like there's no news available.
